Skip to content

A Randomized, Controlled, Multicenter Clinical Study on the Effectiveness of Xiao'er Jiebiao oral liquids in the Treatment of Influenza in Children

Evidence Based Evaluation of Traditional Chinese Medicine Prevention and Treatment Program for Children with Influenza

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003909
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza in Children

Interventions

Sponsors

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with influenza A (H1N1, H3N2) or influenza B virus according to real-time polymerase chain reaction (PCR) or virus culture; 2. Patients aged 5 to 14 years old; 3. Patients with axillary temperature = 38 ?; 4. Patients with at least two general symptoms (headache, chills, myalgia or fatigue) and one respiratory symptom (cough, sore throat or rhinitis); 5. Patients who meet the diagnostic criteria of TCM syndromes; 6. Patients with a course of disease within 72 hours; 7. Patients with written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with bronchitis, pneumonia, pleural effusion and interstitial lung disease on chest X-ray; 2. Patients with bacterial infection indicated by blood routine examination; 3. Patients with suppurative tonsillitis or purulent sputum; 4. Patients with primary diseases, such as blood diseases, bronchial asthma, liver diseases, kidney diseases, chronic congestive heart failure and nervous system diseases; 5. Patients who had taken antiviral drugs (amantadine, rimantadine, zanamivir or oseltamivir phosphate) before the onset and enrollment of the study, or took Chinese herbal medicine or proprietary Chinese medicine. 6. Patients allergic to the study drug; 7. Patients who have taken immunosuppressants in the last 3 months; 8. Patients who participated in another clinical trial within 3 months before participating in this trial; 9. Patients with acute respiratory tract infection, otitis or sinusitis 2 weeks before enrollment; 10. Patients who have been vaccinated with influenza vaccine within 6 months; 11. Other reasons considered by the researchers.

Design outcomes

Primary

MeasureTime frame
Duration of disease;The rate of cure;TCM syndrome score;

Secondary

MeasureTime frame
Frequency of use of antipyretic;Incidence of influenza complications;Defervescence time;Disease severity;Negative conversion rate of influenza virus;

Countries

China

Contacts

Public ContactWang Xuefeng

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

lnzywxf@163.com+86 13840208807

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026